|
|
Blood, 15 June 2006, Vol. 107, No. 12, pp. 4614-4622.
Prepublished online as a Blood First Edition Paper on February 16, 2006; DOI 10.1182/blood-2005-10-4202.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
Donald W. Milligan,
Keith Wheatley,
Timothy Littlewood,
Jenny I. O. Craig,
Alan K. Burnett, for the NCRI Haematological Oncology Clinical Studies Group
From the Department of Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom; the Department of Haematology, John Radcliffe Hospital, Oxford, United Kingdom; the Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom; the University Department of Haematology, Cardiff, United Kingdom; and Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
The optimum chemotherapy schedule for reinduction of patients with high-risk acute myeloid leukemia (relapsed, resistant/refractory, or adverse genetic disease) is uncertain. The MRC AML (Medical Research Council Acute Myeloid Leukemia) Working Group designed a trial comparing fludarabine and high-dose cytosine (FLA) with standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE). Patients were also randomly assigned to receive filgrastim (G-CSF) from day 0 until neutrophil count was greater than 0.5 x 109/L (or for a maximum of 28 days) and all-trans retinoic acid (ATRA) for 90 days. Between 1998 and 2003, 405 patients were entered: 250 were randomly assigned between FLA and ADE; 356 to G-CSF versus no G-CSF; 362 to ATRA versus no ATRA. The complete remission rate was 61% with 4-year disease-free survival of 29%. There were no significant differences in the CR rate, deaths in CR, relapse rate, or DFS between ADE and FLA, although survival at 4 years was worse with FLA (16% versus 27%, P = .05). Neither the addition of ATRA nor G-CSF demonstrated any differences in the CR rate, relapse rate, DFS, or overall survival between the groups. In conclusion these findings indicate that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
How did we get here from there?
- Elihu Estey
Blood 2006 107: 4577.
[Full Text]
[PDF]
Related Letter in Blood Online:
-
Increased mortality with FLA compared with ADE chemotherapy in high-risk AML
- Steven W. Lane, Paula Marlton, Peter N. Mollee, Donald W. Milligan, Alan K. Burnett, and Keith Wheatley
Blood 2006 108: 3950-3951.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. Aplenc, T. A. Alonzo, R. B. Gerbing, B. J. Lange, C. A. Hurwitz, R. J. Wells, I. Bernstein, P. Buckley, K. Krimmel, F. O. Smith, et al.
Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group
J. Clin. Oncol.,
May 10, 2008;
26(14):
2390 - 2395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene
Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection
Ann Intern Med,
September 18, 2007;
147(6):
400 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Heuser, B. Argiropoulos, F. Kuchenbauer, E. Yung, J. Piper, S. Fung, R. F. Schlenk, K. Dohner, T. Hinrichsen, C. Rudolph, et al.
MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML
Blood,
September 1, 2007;
110(5):
1639 - 1647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Milella, M. Konopleva, C. M. Precupanu, Y. Tabe, M. R. Ricciardi, C. Gregorj, S. J. Collins, B. Z. Carter, C. D'Angelo, M. T. Petrucci, et al.
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis
Blood,
March 1, 2007;
109(5):
2121 - 2129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Lane, P. Marlton, P. N. Mollee, D. W. Milligan, A. K. Burnett, and K. Wheatley
Increased mortality with FLA compared with ADE chemotherapy in high-risk AML.
Blood,
December 15, 2006;
108(12):
3950 - 3951.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Gutschalk, C. C. Herold-Mende, N. E. Fusenig, and M. M. Mueller
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Promote Malignant Growth of Cells from Head and Neck Squamous Cell Carcinomas In vivo
Cancer Res.,
August 15, 2006;
66(16):
8026 - 8036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
